[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100561076":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":34,"locations":42,"responsibleParty":199,"collaborators":25,"id":201,"slug":202,"hasResults":203,"nctId":204,"briefTitle":205,"officialTitle":206,"acronym":25,"eligibilityCriteria":207,"healthyVolunteers":203,"sex":208,"minAge":209,"maxAge":210,"enrollmentInfo":211,"targetDuration":25,"studyType":214,"phases":215,"briefSummary":217,"conditions":218,"keywords":220,"overallStatus":45,"whyStopped":25,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":235},{"fullName":5,"class":6},"Alnylam Pharmaceuticals","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"ALN-HTT02","EXPERIMENTAL","Participants will be administered a single dose of ALN-HTT02 during the Double-blind Part of the study. Participants who received ALN-HTT02 in the Double-blind part of the study will not receive an additional dose during the Open-label Part of the study. Participants have the option to receive repeat doses of ALN-HTT02 in the Open-label Extension (OLE) Part of the study.",[13],"Drug: ALN-HTT02",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo + ALN-HTT02","PLACEBO_COMPARATOR","Participants will be administered a single dose of placebo during the Double-blind Part of the study. Participants will have the option to receive a single dose of ALN-HTT02 during the Open-label Part of the study. Participants have the option to receive repeat doses of ALN-HTT02 in the OLE Part of the study.",[13,19],"Drug: Placebo",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","ALN-HTT02 will be administered intrathecally",[9,15],null,{"type":22,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Placebo","Placebo will be administered intrathecally",[15],[31],{"name":32,"affiliation":5,"role":33},"Medical Director","STUDY_DIRECTOR",[35,40],{"name":36,"role":37,"phone":38,"phoneExt":25,"email":39},"Alnylam Clinical Trial Information Line","CONTACT","1-877-ALNYLAM","clinicaltrials@alnylam.com",{"name":36,"role":37,"phone":41,"phoneExt":25,"email":39},"1-877-256-9526",[43,56,64,72,80,90,98,106,114,122,130,138,148,156,164,172,175,183,191],{"facility":44,"status":45,"city":46,"state":25,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":25},"Clinical Trial Site","RECRUITING","Edmonton","T6G 2B7","Canada","CA",{"type":51,"coordinates":52},"Point",[53,54],-113.46871,53.55014,{"lat":54,"lon":53},{"facility":44,"status":45,"city":57,"state":25,"zip":58,"country":48,"countryCode":49,"cosmosGeoPoint":59,"geoPoint":63,"contacts":25},"Montreal","H2W 1T8",{"type":51,"coordinates":60},[61,62],-73.58781,45.50884,{"lat":62,"lon":61},{"facility":44,"status":45,"city":65,"state":25,"zip":66,"country":48,"countryCode":49,"cosmosGeoPoint":67,"geoPoint":71,"contacts":25},"Ottawa","K1Y4E9",{"type":51,"coordinates":68},[69,70],-75.69812,45.41117,{"lat":70,"lon":69},{"facility":44,"status":45,"city":73,"state":25,"zip":74,"country":48,"countryCode":49,"cosmosGeoPoint":75,"geoPoint":79,"contacts":25},"Vancouver","V6T 2B5",{"type":51,"coordinates":76},[77,78],-123.11934,49.24966,{"lat":78,"lon":77},{"facility":44,"status":45,"city":81,"state":25,"zip":82,"country":83,"countryCode":84,"cosmosGeoPoint":85,"geoPoint":89,"contacts":25},"Berlin","10117","Germany","DE",{"type":51,"coordinates":86},[87,88],13.41053,52.52437,{"lat":88,"lon":87},{"facility":44,"status":45,"city":91,"state":25,"zip":92,"country":83,"countryCode":84,"cosmosGeoPoint":93,"geoPoint":97,"contacts":25},"Bochum","44791",{"type":51,"coordinates":94},[95,96],7.21648,51.48165,{"lat":96,"lon":95},{"facility":44,"status":45,"city":99,"state":25,"zip":100,"country":83,"countryCode":84,"cosmosGeoPoint":101,"geoPoint":105,"contacts":25},"Bonn","53127",{"type":51,"coordinates":102},[103,104],7.09549,50.73438,{"lat":104,"lon":103},{"facility":44,"status":45,"city":107,"state":25,"zip":108,"country":83,"countryCode":84,"cosmosGeoPoint":109,"geoPoint":113,"contacts":25},"Dresden","01307",{"type":51,"coordinates":110},[111,112],13.73832,51.05089,{"lat":112,"lon":111},{"facility":44,"status":45,"city":115,"state":25,"zip":116,"country":83,"countryCode":84,"cosmosGeoPoint":117,"geoPoint":121,"contacts":25},"Münster","48149",{"type":51,"coordinates":118},[119,120],7.62571,51.96236,{"lat":120,"lon":119},{"facility":44,"status":45,"city":123,"state":25,"zip":124,"country":83,"countryCode":84,"cosmosGeoPoint":125,"geoPoint":129,"contacts":25},"Taufkirchen","84416",{"type":51,"coordinates":126},[127,128],11.61701,48.0486,{"lat":128,"lon":127},{"facility":44,"status":45,"city":131,"state":25,"zip":132,"country":83,"countryCode":84,"cosmosGeoPoint":133,"geoPoint":137,"contacts":25},"Ulm","89081",{"type":51,"coordinates":134},[135,136],9.99155,48.39841,{"lat":136,"lon":135},{"facility":44,"status":45,"city":139,"state":25,"zip":140,"country":141,"countryCode":142,"cosmosGeoPoint":143,"geoPoint":147,"contacts":25},"Birmingham","B15 2TT","United Kingdom","UK",{"type":51,"coordinates":144},[145,146],-1.89983,52.48142,{"lat":146,"lon":145},{"facility":44,"status":45,"city":149,"state":25,"zip":150,"country":141,"countryCode":142,"cosmosGeoPoint":151,"geoPoint":155,"contacts":25},"Cambridge","CB2 0PY",{"type":51,"coordinates":152},[153,154],0.11667,52.2,{"lat":154,"lon":153},{"facility":44,"status":45,"city":157,"state":25,"zip":158,"country":141,"countryCode":142,"cosmosGeoPoint":159,"geoPoint":163,"contacts":25},"Cardiff","CF103AX",{"type":51,"coordinates":160},[161,162],-3.18,51.48,{"lat":162,"lon":161},{"facility":44,"status":45,"city":165,"state":25,"zip":166,"country":141,"countryCode":142,"cosmosGeoPoint":167,"geoPoint":171,"contacts":25},"Glasgow","G51 4TF",{"type":51,"coordinates":168},[169,170],-4.25763,55.86515,{"lat":170,"lon":169},{"facility":44,"status":45,"city":173,"state":25,"zip":174,"country":141,"countryCode":142,"cosmosGeoPoint":25,"geoPoint":25,"contacts":25},"Greater Manchester","M13 9WL",{"facility":44,"status":45,"city":176,"state":25,"zip":177,"country":141,"countryCode":142,"cosmosGeoPoint":178,"geoPoint":182,"contacts":25},"London","WC1N 3BG",{"type":51,"coordinates":179},[180,181],-0.12574,51.50853,{"lat":181,"lon":180},{"facility":44,"status":45,"city":184,"state":25,"zip":185,"country":141,"countryCode":142,"cosmosGeoPoint":186,"geoPoint":190,"contacts":25},"Oxford","OX3 9DU",{"type":51,"coordinates":187},[188,189],-1.25596,51.75222,{"lat":189,"lon":188},{"facility":44,"status":45,"city":192,"state":25,"zip":193,"country":141,"countryCode":142,"cosmosGeoPoint":194,"geoPoint":198,"contacts":25},"Plymouth","PL6 8DH",{"type":51,"coordinates":195},[196,197],-4.14305,50.37153,{"lat":197,"lon":196},{"type":200,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100561076","phase-1-a-study-to-evaluate-aln-htt02-in-adult-patients-with-huntingtons-disease-100561076",false,"NCT06585449","A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease","A Randomized, Double-blind, Placebo-controlled Study, to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally Administered Single Ascending Doses of ALN-HTT02 in Adult Patients With Huntington's Disease","Inclusion Criteria\n\n* Has stage 2 or early Stage 3 Huntington's disease (HD), per the Huntington's Disease Integrated Staging System (HD-ISS)\n\nExclusion Criteria\n\n* Has significant structural or degenerative neurologic disease other than Huntington's Disease (HD) at screening\n* Has primary or secondary immune compromise at screening due to infections, medical conditions, or chronic therapies\n* Has alanine aminotransferase or aspartate aminotransferase \\>2× upper limit of normal (ULN)\n* Has an estimated glomerular filtration rate (eGFR) of \\\u003C60 mL\u002Fmin\u002F1.73m\\^2 at screening\n* Has received an investigational agent within the last 1 year or 5 half-lives (if known)\n\nNote: other protocol defined inclusion \u002F exclusion criteria apply","ALL","25 Years","70 Years",{"count":212,"type":213},66,"ESTIMATED","INTERVENTIONAL",[216],"PHASE1","The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of single or repeat doses of ALN-HTT02.",[219],"Huntington's Disease",[221,9,222,223,224,225],"siRNA","Intrathecal","HD-ISS Stage 2","HD-ISS early Stage 3","Neurodegenerative disorder","2026-06-10",{"date":228,"type":229},"2026-06-12","ACTUAL",{"date":231,"type":229},"2024-10-14",{"date":233,"type":213},"2028-07-05",{"name":5,"class":6},19]